Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12381699 | 0.72 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL18337095 | 0.70 | L3MBTL1 (0.48) | L3MBTL1ALDH1A1 | |
| SCHEMBL69879 | 0.64 | — | — | |
| SCHEMBL16886922 | 0.62 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL3695099 | 0.62 | L3MBTL1 (0.40) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL13208621 | 0.60 | L3MBTL1 (0.43) | L3MBTL1 | |
| SCHEMBL2568233 | 0.60 | L3MBTL1 (0.39) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL552591 | 0.60 | L3MBTL1 (0.39) | L3MBTL1 | |
| SCHEMBL17962522 | 0.59 | HPGD (0.31) | — | |
| SCHEMBL14383210 | 0.59 | HPGD (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2015-08-20 | — | — | US | disclosed |
| US-8865732-B2 | Heterocyclic compounds and uses thereof | NOVARTIS AG (CH) | 2014-10-21 | — | — | US | disclosed |
| US-8859548-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2014-10-14 | — | — | US | disclosed |
| EP-2470528-B1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-10-01 | — | — | EP | disclosed |
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-20140221374-A1 | RAF KINASE INHIBITORS | RUGA CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| EP-2686317-A2 | RAF KINASE INHIBITORS | Selexagen Therapeutics, Inc. (US) | 2014-01-22 | — | — | EP | disclosed |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS AG (CH) | 2014-01-09 | — | — | US | disclosed |
| US-8563553-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2013-10-22 | — | — | US | disclosed |
| WO-2012125981-A2 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125981-A2 | RAF KINASE INHIBITORS | SELEXAGEN THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2012-09-06 | — | — | US | disclosed |
| US-8242260-B2 | Compounds and compositions as protein kinase inhibitors | NOVARTIS AG (CH) | 2012-08-14 | — | — | US | disclosed |
| EP-2470528-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | Novartis AG (CH) | 2012-07-04 | — | — | EP | disclosed |
| US-8129394-B2 | Heteroaryl-substituted imidazole compounds and uses thereof | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| CN-102015686-A | Novel heterocyclic compounds and uses therof | NOVARTIS AG | 2011-04-13 | — | — | CN | disclosed |
| WO-2011023773-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-03 | — | — | WO | disclosed |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-03-03 | — | — | US | disclosed |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | NOVARTIS AG (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221374-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | L3MBTL1 2909/4885ALDH1A1 2173/4885SMN1; SMN2 2644/4885 |
| US-20110052578-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | L3MBTL1 1967/4885ALDH1A1 3869/4885SMN1; SMN2 3811/4885 |
| US-20150232452-A1 | NOVEL RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | L3MBTL1 3183/4885ALDH1A1 2652/4885SMN1; SMN2 2837/4885 |
| US-20120225899-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | L3MBTL1 1967/4885ALDH1A1 3869/4885SMN1; SMN2 3811/4885 |
| US-20100003246-A1 | Novel heterocyclic compounds and uses therof | BRAF, ARAF, KRAS | L3MBTL1 1865/4885ALDH1A1 3257/4885SMN1; SMN2 3581/4885 |
| US-20140011825-A1 | Compounds and Compositions as Protein Kinase Inhibitors | RAF1, BRAF, ARAF | L3MBTL1 1967/4885ALDH1A1 3869/4885SMN1; SMN2 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.